Ignite Creation Date:
2024-05-06 @ 2:35 PM
Last Modification Date:
2024-10-26 @ 1:34 PM
Study NCT ID:
NCT04369586
Status:
COMPLETED
Last Update Posted:
2021-04-09
First Post:
2020-04-24
Brief Title:
A Phase I Clinical Trial of Meplazumab in Healthy Volunteer
Sponsor:
Xijing Hospital
Organization:
Xijing Hospital
Study Overview
Official Title:
A Single Center Double-blinded Placebo-controlled Phase I Clinical Trial in Healthy Volunteer to Evaluate Tolerance and Pharmacokinetics of Meplazumab of Injection
Status:
COMPLETED
Status Verified Date:
2020-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single center double-blinded placebo-controlled phase I clinical trail in healthy volunteer of meplazumab for injection The primary objective of this phase I trial is to evaluate the safety tolerability pharmacokinetic characteristics and occupancy characteristics of peripheral blood cell receptors of meplazumab in healthy volunteer and provide a reference for the dosage of meplazumab in phase II clinical trial
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None